The Lancet Neurology Publishes Positive Results of AFFiRiS’ Phase 1 Trial with PD01A In Parkinson’s Disease Patients

The Lancet Neurology Publishes Positive Results of AFFiRiS’ Phase 1 Trial with PD01A In Parkinson’s Disease Patients
VIENNA, AUSTRIA / ACCESSWIRE / June 18, 2020 / AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detai ... read more
Source: Bing NewsPublished on 2020-06-17